Beatrice De Vos

TL;DR: Two oral doses of the live attenuated G1P[8] HRV vaccine were highly efficacious in protecting infants against severe rotavirus gastroenteritis, significantly reduced the rate of severe gastroenteropathy from any cause, and were not associated with an increased risk of intussusception.

TL;DR: Two doses of RIX4414 were effective against severe rotavirus gastroenteritis during the first 2 years of life in a Latin American setting and inclusion of Rix4414 in routine paediatric immunisations should reduce the burden of rotav virus gastroEnteritis worldwide.

TL;DR: Two doses of RIX4414 are highly efficacious, providing cross-protection against any and severe rotavirus gastroenteritis and hospitalization to infants in Latin America and proof of concept that the monovalent G1P1A P[8] human rotav virus vaccine elicits cross- protection against the G9 strain.

TL;DR: RIX4414 strain of G1 human rotavirus vaccine was well-tolerated, immunogenic and efficacious in infants againstRotavirus gastroenteritis during a 2-year period, and a higher dose of this vaccine may be considered for future efficacy trials.

TL;DR: Results show prospects for widespread use of Rotarix to reduce rotavirus disease burden and warrant continued worldwide evaluation.